Real World Evidence Solutions Market Report 2026

The real world evidence solutions market size has grown rapidly in recent years. It will grow from $2.33 billion in 2025 to $2.7 billion in 2026 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to increasing availability of real-world healthcare data, rising demand for post-approval evidence, growing focus on drug safety monitoring, expansion of electronic health record adoption, early regulatory acceptance of rwe.

The real world evidence solutions market size is expected to see rapid growth in the next few years. It will grow to $4.81 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to data-driven regulatory decision making, growing use of rwe in reimbursement decisions, expansion of precision medicine initiatives, increasing integration of real-time healthcare data, rising adoption of ai-enabled evidence platforms. Major trends in the forecast period include increasing use of advanced analytics in rwe studies, growing integration of ehr and claims data, rising adoption of AI-driven evidence generation, expansion of rwe in regulatory submissions, enhanced focus on post-market safety monitoring.

The expanding geriatric population is expected to drive the growth of the real-world evidence solutions market in the coming years. The geriatric population includes individuals aged 65 years and above, who face higher health risks due to factors such as postural hypotension, balance issues, and gait impairments. Aging also increases susceptibility to chronic conditions including stroke, cardiovascular diseases, type 2 diabetes, arthritis, and cancer. For instance, in January 2024, according to data published by the Population Reference Bureau, a US-based nonprofit organization, the population of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% rise. In addition, this age group’s share of the total population is expected to grow from 17% to 23%. Therefore, the growing geriatric population is driving the growth of the real-world evidence solutions market.

Major companies operating in the real-world evidence solutions market are focusing on introducing innovative offerings, such as new real-world evidence solutions services, to strengthen evidence-based medicine. Real-world evidence solutions services are designed to generate and analyze clinical insights related to the use, benefits, and risks of medical products by leveraging real-world data obtained from routine healthcare delivery. For instance, in October 2023, Maxis Clinical Sciences, a US-based clinical research consultancy serving small to medium-sized pharmaceutical and life sciences companies, launched a new real-world evidence solutions service. The RWE Solutions offering from Maxis Clinical Sciences integrates multiple real-world data sources, including patient-reported outcomes and data from wearable devices, with the aim of improving patient engagement and enhancing data quality.

In March 2024, eMed LLC, a US-based telehealth and diagnostics company, acquired Science 37 Holdings Inc. through a tender offer valued at $5.75 per share. Through this acquisition, eMed aims to strengthen its real-world evidence capabilities by incorporating Science 37’s decentralized Metasite platform, which allows patients to participate in clinical studies remotely and supports the collection of real-world data beyond traditional research sites. Science 37 Holdings Inc. is a US-based decentralized clinical trials company focused on increasing study access through virtual participation and generating high-quality real-world patient data.

Major companies operating in the real world evidence solutions market are Anthem Inc., Cegedim Health Data, Clarivate PLC, Cognizant Technology Solutions Corporation, Flatiron Health Inc., International Business Machines Corporation, ICON plc, IQVIA Holdings Inc., Medpace Holdings Inc., Optum Inc., Oracle Corporation, PAREXEL International Corporation, PPD Inc., SAS Institute Inc., Syneos Health, Symphony Innovation LLC, UnitedHealth Group Incorporated, Deloitte Touche Tohmatsu Limited, Informa PLC, Palantir Technologies, UDG Healthcare PLC, Elevance Health Inc., Covance Consulting Ltd., Clinipace Worldwide, Evidera Inc., Pharmerit International, Analysis Group Inc., HealthCore Inc., Inovalon Holdings Inc., KMK Consulting Inc.

North America was the largest region in the real world evidence solutions market in 2025. Asia-Pacific is expected to be the fastest-growing region in the real world evidence solutions market share during the forecast period. The regions covered in the real world evidence solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the real world evidence solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the real world evidence solutions market by increasing costs associated with imported data infrastructure hardware, cloud services components, analytics platforms, and cybersecurity tools used in large-scale healthcare data processing. Pharmaceutical and healthcare organizations in North America and Europe are most affected due to reliance on globally sourced digital infrastructure, while Asia-Pacific faces cost pressures in data platform deployment. These tariffs are raising operational costs and slowing platform expansion initiatives. However, they are also encouraging localized data hosting, regional analytics development, and increased investment in domestic health data ecosystems, supporting long-term market resilience.

The real world evidence solutions market research report is one of a series of new reports that provides real world evidence solutions market statistics, including real world evidence solutions industry global market size, regional shares, competitors with a real world evidence solutions market share, detailed real world evidence solutions market segments, market trends and opportunities, and any further data you may need to thrive in the real world evidence solutions industry. This real world evidence solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Real-world evidence solutions refer to clinical insights generated from data collected outside of controlled clinical trial settings, using sources such as electronic health records, insurance claims databases, and patient registries. These insights are used to evaluate the safety, effectiveness, and utilization of medical treatments in real-world healthcare settings.

The key components of real-world evidence solutions include services, data sets, clinical setting data, claims data, pharmacy data, and patient-powered data. Services involve the delivery of activities or tasks for commercial purposes. These solutions are applied across therapeutic areas such as oncology, cardiovascular disease, neurology, immunology, and others. They support applications including drug development and regulatory approval, medical device development and approval, reimbursement and coverage decisions, regulatory decision making, and post-market safety and adverse event monitoring. The primary end users of real-world evidence solutions include pharmaceutical and medical device companies, healthcare providers, healthcare payers, and other end users.

The real-world evidence solutions market consists of sales of solutions that are used in randomized trials, large simple trials, pragmatic trials, and observational studies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.